Novel Therapies in Development for Diabetic Macular Edema

Aniruddha Agarwal, Rubbia Afridi, Muhammad Hassan, Mohammad Ali Sadiq, Yasir J. Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Diabetic macular edema (DME) secondary to diabetic retinopathy (DR) is a major cause for functional visual loss in the developed world. Laser photocoagulation has been used for decades in the treatment of DME. However, the advent of anti-vascular endothelial growth factor (anti-VEGF) has revolutionized the treatment of DME. Three important anti-VEGF agents whose efficacy has been well established via phase III clinical trials include ranibizumab, bevacizumab, and aflibercept. However, even in the era of anti-VEGF therapies, there are some challenges that retina specialists have to confront in managing patients with DME. These include the need for frequent treatment and an unpredictable response to therapy. There is evidence to suggest that pathways other than the VEGF pathway may be playing a role in the development of DME. Thus, extensive research is focused on development of novel agents that target these pathways. This review focuses on novel therapeutic agents in development, which may be used as a monotherapy or in combination with anti-VEGF agents, for the management of DME in the future.

Original languageEnglish (US)
Article number75
JournalCurrent diabetes reports
Issue number10
StatePublished - Oct 22 2015


  • Anti-VEGF
  • Clinical trials
  • DARPin
  • Diabetic macular edema
  • Diabetic retinopathy
  • Stem cell therapy
  • VAP-1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Novel Therapies in Development for Diabetic Macular Edema'. Together they form a unique fingerprint.

Cite this